Testing Two Medicines Together for Hard-to-Treat Schizophrenia
Tests an NMDA-enhancing drug with an anti-inflammatory drug in adults with ultra-resistant schizophrenia.
Plain-language title generated from the registry record
Registry title: Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05240976, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT05240976
- Record updated
- 24 March 2026
- Original description
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.Read full original descriptionShow less
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia; Are treatment-resistant to standard treatments of at least two specific antipsychotics before clozapine treatment; Are receiving adequate trials of clozapine for more than 12 weeks but without satisfactory response; PANSS total score ≥ 70; SANS total score ≥ 40; Have sufficient education to communicate effectively and are capable of completing the assessments of the study; Agree to participate in the study and provide informed consent.
Exclusion: DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder; History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study; Clinically significant laboratory screening tests (including blood routine, biochemical tests); Pregnancy or lactation; Inability to follow protocol.